RxDoctor Payments Data

Farah Morgan, MD

Endocrinology, Diabetes & Metabolism · Cherry Hill, NJNPI 1699966614

Payments from drug & device makers

$580in general payments, 2019–2025

Across 26 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$294
  • AstraZeneca$116
  • Novo Nordisk$78
  • Dexcom, Inc.$38
  • Sanofi-aventis U.S. LLC$17
  • Currax Pharmaceuticals LLC$12
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$55696%
  • Education$244%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$580 in reported general payments places this provider in the 25th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey

Medicare billing

Part B allowed, 2024
$102,995
Medicare patients
477
Services billed
944

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide362$604,535
MounjaroTirzepatide187$266,770
TrulicityDulaglutide136$217,177
JardianceEmpagliflozin121$148,596
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/737$63,713
Humalog Kwikpen U-100Insulin Lispro168$58,141
JanuviaSitagliptin Phosphate48$55,542
Fiasp FlextouchInsulin Aspart (Niacinamide)38$50,416
FarxigaDapagliflozin Propanediol50$50,263
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog105$47,832
Humalog Kwikpen U-200Insulin Lispro11$44,297
Lantus SolostarInsulin Glargine,hum.Rec.Anlog281$42,214
Lyumjev Kwikpen U-100Insulin Lispro-Aabc23$40,859
Tresiba Flextouch U-200Insulin Degludec21$39,176
Tresiba Flextouch U-100Insulin Degludec49$36,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$78$645,865397 claims
Lilly USA, LLCMounjaro, Trulicity, Baqsimi, Humalog$12$528,340442 claims
AstraZenecaFarxiga$116$50,26350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →